TickerFacts.

Insight Molecular Diagnostics Inc. (IMDX): Depreciation & Amortization

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2021-12-31, 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$2.19M
Year ended 2025-12-31
$2.44M
Trailing 12 months to 2026-06-30
+12.7%
3-year compound annual growth
2020-12-31: $313.0K2021-12-31: $800.0K2022-12-31: $1.53M2023-12-31: $1.59M2024-12-31: $1.48M2025-12-31: $2.19M$2.19M
2020-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$2.19M+48.4%2026-03-26, From 2025-01-01
2024-12-31$1.48M-7.3%2026-03-26, From 2024-01-01
2023-12-31$1.59M+4.2%2025-03-24, From 2023-01-01
2022-12-31$1.53Mn/c2024-04-16, From 2022-01-01
2021-12-31$800.0Kn/c2023-04-12, From 2021-01-01
2020-12-31$313.0Kn/a2022-03-11, From 2020-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$2.19M+48.4%
Biomerica Inc (BMRA)2026-05-31$77.0K-11.5%
Aspira Women's Health Inc. (AWHL)2025-12-31$112.0K+21.7%
Volitionrx Ltd (VNRX)2025-12-31$983.7K-11.6%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$3.38M+6.4%
Immucell Corp (ICCC)2025-12-31$2.78M+2.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$6.34M-3.6%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$9.77M-5.0%
Myriad Genetics Inc (MYGN)2025-12-31$53.70M-12.3%

Compare IMDX, BMRA, AWHL, VNRX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗